Healthcare firm swoops on specialist manufacturer in £31m deal
Greater Manchester firm Scapa has completed the £31m acquisition of a specialist wound management manufacturing business.
Ashton based Scapa announced it was buying Sussex based Systagenix Wound Management Manufacturing in September and the deal has now been completed.
In addition, Scapa and Acelity have now entered into the exclusive five-year manufacturing and supply agreement for Systagenix advanced wound care products that are currently manufactured in the Gargrave facility.
Scapa is a global specialist in adhesive products for the healthcare and industrial sectors.
It is paying cash for the Systagenix, subject to conditions.
Systagenix is a global leader in advanced wound care, developing and marketing therapeutic solutions and supplying more than 20 million advanced wound dressings per month to more than 75 countries.
Its involvement in skin and wound care began with innovative wound care treatments developed by a team of R&D scientists at the Gargrave Centre of Excellence for Wound Healing in North Yorkshire in 1934.
Systagenix Wound Management Limited and the Systagenix Brand will remain part of Acelity.
Scapa Group said Systagenix’s manufacturing operations, sterilisation services, warehouse facilities and the R&D and regulatory support functions in Gargrave will be acquired as part of the deal.
The addition of the 335,000 sq ft Gargrave site will position Scapa as one of the leading global B2B manufacturers of advanced wound care products.
Scapa Group chief executive Heejae Chae said: “The transaction marks a milestone in our healthcare journey from a material supplier to a global healthcare company.
“It bridges the final gaps in our value proposition in capabilities, services and footprint.
“The Gargrave facility will serve as our European centre of excellence with its state-of-the-art manufacturing facility and significant innovation and development capability.
“Additionally, the transaction will further strengthen our strategic relationship with Acelity by supporting its strategy for continued growth as the leading wound care company in the world.”
In March this year AIM-listed Scapa Group bought American company BioMed Laboratories for £25m.
In September, 2017, Scapa bought the entire share capital of Market Industries, Controlled Environment Equipment Corp and CMark Films for £7.68m.
